Zoryve FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 2, 2024.
FDA Approved: Yes (First approved July 29, 2022)
Brand name: Zoryve
Generic name: roflumilast
Dosage form: Cream and Foam
Company: Arcutis Biotherapeutics, Inc.
Treatment for: Plaque Psoriasis, Seborrheic Dermatitis
Zoryve (roflumilast) is a topical phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of plaque psoriasis (cream formulation) and seborrheic dermatitis (foam formulation).
- Zoryve cream 0.3% is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older.
Zoryve foam 0.3% is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. - Zoryve contains roflumilast which is a highly potent and selective inhibitor of phosphodiesterase type 4 (PDE4). PDE4 is an intracellular enzyme that drives overactive immune responses in a range of inflammatory diseases including psoriasis, eczema, and COPD.
- Roflumilast was first approved by the U.S. Food and Drug Administration (FDA) in 2011 as an oral formulation under the brand name Daliresp, which is used to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD).
- Zoryve is applied to the affected areas once daily.
- Zoryve cream: Common adverse reactions include diarrhea, headache, insomnia, application site pain, upper respiratory tract infections, and urinary tract infections.
Zoryve foam: Common adverse reactions include nasopharyngitis, nausea, and headache.
Development timeline for Zoryve
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
